RedHill Biopharma Ltd. focuses on the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers in Israel. The company was founded in 2009 and is based in Tel Aviv, Israel.
The presentation will be available on the Company's website, http://ir.redhillbio.com/events on July 7, 2020 for a period of 30 days. Pre-clinical data have demonstrated both anti-inflammatory and anti-viral activities of opaganib, with the potential to reduce lung inflammatory disorders, such as pneumonia, and mitigate pulmonary fibrotic damage.
RedHill Biopharma ([[RDHL]] -6.5%) announces that the UK Medicines & Healthcare products Regulatory Agency ((MHRA)) has approved the Company’s clinical trial application to commence a Phase 2/3 study evaluating opaganib in patients hospitalized with severe SARS-CoV-2 infection (the cause of COVID-19) and pneumonia.The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 study will enroll...
RedHill has also submitted CTA applications for this study in Russia and Italy and plans to expand the study to additional countries. The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 study is set to enroll up to 270 subjects with severe COVID-19 pneumonia requiring hospitalization and treatment with supplemental oxygen.